BioCryst Q3 2026 net income more than doubles to $37.92 million

By Public Technologies12:15 (UTC), 4 November 2026 Updated

BioCryst Pharmaceuticals’ third-quarter 2026 net income more than doubled year-over-year to $37.92 million.
Total revenue rose 13% to $180.3 million, benefiting from CareMed’s initial ORLADEYO inventory build during the specialty pharmacy transition.
FDA approval in October expanded ORLADEYO oral pellets to patients aged 12 and older following the August pediatric launch.
Raised 2026 total revenue guidance to $715 million to $730 million, maintaining ORLADEYO revenue guidance at $625 million to $645 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED9869598) on November 04, 2026, and is solely responsible for the information contained therein.